Related Experiment Video
Updated: Jul 16, 2026
07:54
Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test
Published on: January 19, 2024
Twinrix vaccination schedules among injecting drug users
Nancy Brim1, Nickolas Zaller, Lynn E Taylor
1Brown Medical School, Providence, Rhode Island, USA, 2The Miriam Hospital, 164 Summit Ave, Providence, RI 02906, USA. nzaller@lifespan.org
Expert Opinion on Biological Therapy
|February 21, 2007
Summary
This review examines the accelerated Twinrix vaccine schedule for hepatitis A (HAV) and hepatitis B (HBV) in injecting drug users (IDUs). More evidence is needed to confirm if this faster schedule improves protection against both viruses in this high-risk group.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Twinrix is the sole vaccine offering combined protection against Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV).
- Standard Twinrix vaccination involves 0, 1, and 6-month intervals, often unmet by high-risk groups like injecting drug users (IDUs).
- An accelerated schedule (0, 7, 21 days with a 12-month booster) exists for Twinrix.
Purpose of the Study:
- To review existing literature on the efficacy of the accelerated Twinrix vaccination schedule in IDUs.
- To assess if the accelerated schedule enhances protection against HAV and HBV in IDUs compared to the standard schedule.
- To identify gaps in evidence regarding the accelerated Twinrix schedule's impact on IDUs.
Main Methods:
- Literature review of studies on Twinrix vaccination in IDUs.
- Analysis of data concerning accelerated versus standard vaccination schedules.
- Evaluation of immune response and completion rates in IDUs.
Main Results:
- The review found insufficient evidence to determine if the accelerated Twinrix schedule provides superior protection against HAV and HBV in IDUs.
- Completion rates and long-term immunity data for the accelerated schedule in IDUs are limited.
- Current literature does not definitively support the accelerated schedule for maximizing protection in this population.
Conclusions:
- More research is required to validate the effectiveness of the accelerated Twinrix schedule for HAV and HBV prevention in IDUs.
- The study highlights a need for evidence-based vaccination strategies tailored to high-risk populations like IDUs.
- Further investigation should focus on adherence, immunogenicity, and long-term protection offered by accelerated schedules in vulnerable groups.
Related Concept Videos
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:19Dosage Interval and Administration Route: Determination Methods
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to individual...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...